Table of Contents 2
List of Tables 4
List of Figures 4
Noxxon Pharma AG Spshot 5
Noxxon Pharma AG Overview 5
Key Facts 5
Noxxon Pharma AG - Research and Development Overview 6
Key Therapeutic Areas 6
Noxxon Pharma AG - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Noxxon Pharma AG - Pipeline Products Glance 11
Noxxon Pharma AG - Clinical Stage Pipeline Products 11
Phase II Products/Combition Treatment Modalities 11
Phase I Products/Combition Treatment Modalities 12
Noxxon Pharma AG - Early Stage Pipeline Products 13
Preclinical Products/Combition Treatment Modalities 13
Noxxon Pharma AG - Drug Profiles 14
emapticap pegol - Drug Profile 14
Product Description 14
Mechanism Of Action 14
R&D Progress 14
lexaptepid pegol - Drug Profile 16
Product Description 16
Mechanism Of Action 16
R&D Progress 16
NOXD-19 - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
NOXD-20 - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
NOXD-21 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
NOXG-15 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
NOXG-16 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
NOXL-41 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NOXS-93 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
olaptesed pegol - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Noxxon Pharma AG - Pipeline Alysis 29
Noxxon Pharma AG - Pipeline Products by Target 29
Noxxon Pharma AG - Pipeline Products by Route of Administration 30
Noxxon Pharma AG - Pipeline Products by Molecule Type 31
Noxxon Pharma AG - Pipeline Products by Mechanism of Action 32
Noxxon Pharma AG - Dormant Projects 33
Noxxon Pharma AG - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36